Medical Policy Updates

Medical Policy Update for January 4, 2022

Policy Name Updated Criteria
Omalizumab (Xolair®) Added requirement for use of the self-administered product unless certain criteria are met. For nasal polyposis indication: added requirement of step through Xhance, removed requirement for nasal saline irrigations, and added requirement for previous surgery for nasal polyps. Adjusted criteria for chronic rhinosinusitis with nasal polyposis to allow for patients who are not a candidate for sinus surgery.